Corrigendum to "A novel SNP in a vitamin D response element of the CYP24A1 promoter reduces protein binding, transactivation, and gene expression" [J. Steroid Biochem. Mol. Biol. 112 (2008) 47-54] (DOI:10.1016/j.jsbmb.2008.08.009);A novel SNP in a vitamin D response element of the CYP24A1 promoter reduces protein binding, transactivation, and gene expression

Journal of Steroid Biochemistry and Molecular Biology

Volumn 112, Issue 1-3, 2008, Pages 47-54

  Roff, Alanna ^a   Wilson, Robin Taylor ^a  

^a PENN STATE CANCER INSTITUTE   (United States)

Author keywords

1 ,25(OH)2D3; 24 Hydroxylase; CYP24A1; Promoter; Single nucleotide polymorphism; VDRE; Vitamin D receptor

Indexed keywords

CALCITRIOL; CYTOCHROME P450 24A1; CYTOCHROME P450 ISOENZYME; RETINOID X RECEPTOR ALPHA; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

AFRICAN AMERICAN; ARTICLE; CANCER RISK; CATABOLISM; CONTROLLED STUDY; ETHNIC GROUP; GENE EXPRESSION REGULATION; GENE INDUCTION; GENOTYPE; HUMAN; HUMAN CELL; LYMPHOCYTE; LYMPHOCYTE CULTURE; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; RECEPTOR BINDING; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSACTIVATION; VITAMIN D RESPONSIVE ELEMENT; WILD TYPE;

EID: 55349087215     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2009.09.003     Document Type: Erratum

References (39)

1. Deeb K.K., Trump D.L., and Johnson C.S. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat. Rev. Cancer 7 9 (2007) 684-700
2. Jin C.H., and Pike J.W. Human vitamin D receptor-dependent transactivation in Saccharomyces cerevisiae requires retinoid X receptor. Mol. Endocrinol. 10 2 (1996) 196-205
3. Umesono K., Murakami K.K., Thompson C.C., and Evans R.M. Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 receptors. Cell 65 7 (1991) 1255-1266
4. Harris S.S., and Dawson-Hughes B. Seasonal changes in plasma 25-hydroxyvitamin D concentrations of young American black and white women. Am. J. Clin. Nutr. 67 6 (1998) 1232-1236
5. Harris S.S., Soteriades E., Coolidge J.A., Mudgal S., and Dawson-Hughes B. Vitamin D insufficiency and hyperparathyroidism in a low income, multiracial, elderly population. J. Clin. Endocrinol. Metab. 85 11 (2000) 4125-4130
6. Zadshir A., Tareen N., Pan D., Norris K., and Martins D. The prevalence of hypovitaminosis D among US adults: data from the NHANES III. Ethn. Dis. 15 4 Suppl. 5 (2005) S5-97-S5-101
7. Holick M.F. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am. J. Clin. Nutr. 80 6 Suppl. (2004) 1678S-1688S
8. Lou Y.R., Qiao S., Talonpoika R., Syvala H., and Tuohimaa P. The role of Vitamin D3 metabolism in prostate cancer. J. Steroid Biochem. Mol. Biol. 92 4 (2004) 317-325
9. Peehl D.M., and Feldman D. Interaction of nuclear receptor ligands with the Vitamin D signaling pathway in prostate cancer. J. Steroid Biochem. Mol. Biol. 92 4 (2004) 307-315
10. Trump D.L., Hershberger P.A., Bernardi R.J., Ahmed S., et al. Anti-tumor activity of calcitriol: pre-clinical and clinical studies. J. Steroid Biochem. Mol. Biol. 89-90 1-5 (2004) 519-526
11. Jemal A., Clegg L.X., Ward E., Ries L.A., et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 101 1 (2004) 3-27
12. Jemal A., Siegel R., Ward E., Murray T., et al. Cancer statistics, 2007. CA Cancer J. Clin. 57 1 (2007) 43-66
13. Geronimus A.T., Bound J., Keene D., and Hicken M. Black-white differences in age trajectories of hypertension prevalence among adult women and men, 1999-2002. Ethn. Dis. 17 1 (2007) 40-48
14. Uitterlinden A.G., Fang Y., Van Meurs J.B., Pols H.A., and Van Leeuwen J.P. Genetics and biology of vitamin D receptor polymorphisms. Gene 338 2 (2004) 143-156
15. Slattery M.L. Vitamin D receptor gene (VDR) associations with cancer. Nutr. Rev. 65 8 Pt 2 (2007) S102-S104
16. Gross C., Krishnan A.V., Malloy P.J., Eccleshall T.R., et al. The vitamin D receptor gene start codon polymorphism: a functional analysis of FokI variants. J. Bone Miner. Res. 13 11 (1998) 1691-1699
17. Gross C., Musiol I.M., Eccleshall T.R., Malloy P.J., and Feldman D. Vitamin D receptor gene polymorphisms: analysis of ligand binding and hormone responsiveness in cultured skin fibroblasts. Biochem. Biophys. Res. Commun. 242 3 (1998) 467-473
18. Arai H., Miyamoto K., Taketani Y., Yamamoto H., et al. A vitamin D receptor gene polymorphism in the translation initiation codon: effect on protein activity and relation to bone mineral density in Japanese women. J. Bone Miner. Res. 12 6 (1997) 915-921
19. McCullough M.L., Stevens V.L., Diver W.R., Feigelson H.S., et al. Vitamin D pathway gene polymorphisms, diet, and risk of postmenopausal breast cancer: a nested case-control study. Breast Cancer Res. 9 1 (2007) R9
20. Chen K.S., and DeLuca H.F. Cloning of the human 1 alpha,25-dihydroxyvitamin D-3 24-hydroxylase gene promoter and identification of two vitamin D-responsive elements. Biochim. Biophys. Acta 1263 1 (1995) 1-9
21. Armbrecht H.J., Hodam T.L., Boltz M.A., Partridge N.C., et al. Induction of the vitamin D 24-hydroxylase (CYP24) by 1,25-dihydroxyvitamin D3 is regulated by parathyroid hormone in UMR106 osteoblastic cells. Endocrinology 139 8 (1998) 3375-3381
22. Haussler M.R., Whitfield G.K., Haussler C.A., Hsieh J.C., et al. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J. Bone Miner. Res. 13 3 (1998) 325-349
23. Arbour N.C., Ross T.K., Zierold C., Prahl J.M., and DeLuca H.F. A highly sensitive method for large-scale measurements of 1,25-dihydroxyvitamin D. Anal. Biochem. 255 1 (1998) 148-154
24. Zou A., Elgort M.G., and Allegretto E.A. Retinoid X receptor (RXR) ligands activate the human 25-hydroxyvitamin D3-24-hydroxylase promoter via RXR heterodimer binding to two vitamin D-responsive elements and elicit additive effects with 1,25-dihydroxyvitamin D3. J. Biol. Chem. 272 30 (1997) 19027-19034
25. Toell A., Polly P., and Carlberg C. All natural DR3-type vitamin D response elements show a similar functionality in vitro. Biochem. J. 352 Pt 2 (2000) 301-309
26. Thompson P.D., Jurutka P.W., Whitfield G.K., Myskowski S.M., et al. Liganded VDR induces CYP3A4 in small intestinal and colon cancer cells via DR3 and ER6 vitamin D responsive elements. Biochem. Biophys. Res. Commun. 299 5 (2002) 730-738
27. Kim S., Yamazaki M., Zella L.A., Shevde N.K., and Pike J.W. Activation of receptor activator of NF-kappaB ligand gene expression by 1,25-dihydroxyvitamin D3 is mediated through multiple long-range enhancers. Mol. Cell Biol. 26 17 (2006) 6469-6486
28. Zella L.A., Kim S., Shevde N.K., and Pike J.W. Enhancers located within two introns of the vitamin D receptor gene mediate transcriptional autoregulation by 1,25-dihydroxyvitamin D3. Mol. Endocrinol. 20 6 (2006) 1231-1247
29. Holick C.N., Stanford J.L., Kwon E.M., Ostrander E.A., et al. Comprehensive association analysis of the vitamin D pathway genes, VDR, CYP27B1, and CYP24A1, in prostate cancer. Cancer Epidemiol. Biomarkers Prev. 16 10 (2007) 1990-1999
30. The International HapMap Project, Nature 426 (6968) (2003) 789-796.
31. Narvaez C.J., Byrne B.M., Romu S., Valrance M., and Welsh J. Induction of apoptosis by 1,25-dihydroxyvitamin D3 in MCF-7 Vitamin D3-resistant variant can be sensitized by TPA. J. Steroid Biochem. Mol. Biol. 84 2-3 (2003) 199-209
32. Jensen S.S., Madsen M.W., Lukas J., Bartek J., and Binderup L. Sensitivity to growth suppression by 1alpha,25-dihydroxyvitamin D(3) among MCF-7 clones correlates with Vitamin D receptor protein induction. J. Steroid Biochem. Mol. Biol. 81 2 (2002) 123-133
33. Frohlich B.T., De Bernardez Clark E.R., Siber G.R., and Swartz R.W. Improved pertussis toxin production by Bordetella pertussis through adjusting the growth medium's ionic composition. J. Biotechnol. 39 3 (1995) 205-219
34. Jurutka P.W., Remus L.S., Whitfield G.K., Thompson P.D., et al. The polymorphic N terminus in human vitamin D receptor isoforms influences transcriptional activity by modulating interaction with transcription factor IIB. Mol. Endocrinol. 14 3 (2000) 401-420
35. van Etten E., Verlinden L., Giulietti A., Ramos-Lopez E., Branisteanu D.D., Ferreira G.B., Overbergh L., Verstuyf A., Bouillon R., Roep B.O., Badenhoop K., and Mathieu C. The vitamin D receptor gene FokI polymorphism: functional impact on the immune system. Eur. J. Biochem. 37 2 (2007) 395-405
36. Wang Q., Yang W., Uytingco M.S., Christakos S., and Wieder R. 1,25-Dihydroxyvitamin D3 and all-trans-retinoic acid sensitize breast cancer cells to chemotherapy-induced cell death. Cancer Res. 60 7 (2000) 2040-2048
37. Zhao X.Y., Peehl D.M., Navone N.M., and Feldman D. 1Alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms. Endocrinology 141 7 (2000) 2548-2556
38. Matusiak D., and Benya R.V. CYP27A1 and CYP24 expression as a function of malignant transformation in the colon. J. Histochem. Cytochem. 55 12 (2007) 1257-1264
39. Tan J., Dwivedi P.P., Anderson P., Nutchey B.K., et al. Antineoplastic agents target the 25-hydroxyvitamin D3 24-hydroxylase messenger RNA for degradation: implications in anticancer activity. Mol. Cancer Ther. 6 12 Pt 1 (2007) 3131-3138